Companies Madrigal Pharmaceuticals, Inc

Madrigal Pharmaceuticals (MDGL): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Madrigal Pharmaceuticals, Inc’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$19,206,341CEO Bill Sibold · source

Say-on-pay support97.13%Latest vote · source

CEO vs. named peers75th pct.Of 12 peer CEOs

CEO pay ratio47:1To the median employee · source

CEO pay, last three years

$32,268,400FY2023
$12,214,250FY2024
$19,206,341FY2025

CEO total pay was $19,206,341 in fiscal 2025, up from $12,214,250 in fiscal 2024.

FY2025: salary $918,531 · bonus $0 · stock awards $12,297,850 · option awards $4,537,146

Executives and directors

Carole Huntsman · CCO David Soergel · EVP Rebecca Taub · Executive Bill Sibold · CEO Mardi Dier · CFO Shannon Kelley · General Counsel Daniel J. Brennan · Independent Director Fred B. Craves, Ph.D · Former director (through FY2025)Jacqualyn A. Fouse, Ph.D · Independent Director James M. Daly · Independent Director Julian C. Baker · Chair of the Board Kenneth M. Bate · Former director (through FY2025)Paul A. Friedman, M.D · Director Raymond Cheong, M.D., Ph.D · Independent Director Richard S. Levy, M.D · Independent Director

Frequently asked questions

Who was the highest-paid executive at Madrigal Pharmaceuticals, Inc in fiscal 2025?

As disclosed, Bill Sibold (President and Chief Executive Officer) was the highest-paid executive at Madrigal Pharmaceuticals, Inc in fiscal 2025, with total compensation of $19,206,341.

How does Madrigal Pharmaceuticals, Inc's chief executive pay compare to its disclosed peer group?

As disclosed, Bill Sibold's total compensation ranked at the 75th percentile of Madrigal Pharmaceuticals, Inc's disclosed peer group.

What is Madrigal Pharmaceuticals, Inc's CEO-to-median employee pay ratio?

As disclosed, Madrigal Pharmaceuticals, Inc's CEO-to-median employee pay ratio was 47:1.

How did shareholders vote on Madrigal Pharmaceuticals, Inc's executive compensation?

As disclosed, 97.13% of shareholders supported Madrigal Pharmaceuticals, Inc's executive compensation in the latest say-on-pay vote.

How much does Madrigal Pharmaceuticals, Inc spend in total on board compensation for fiscal 2025?

As disclosed, Madrigal Pharmaceuticals, Inc reported total board compensation of $4,341,973 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Bill Sibold	$918,531	$0	$12,297,850	$4,537,146	$1,438,814	$0	$14,000	$19,206,341
President and Chief Executive Officer
David Soergel	418,182	75,000	5,911,809	2,201,587	584,100	0	0	9,190,678
Executive Vice President and Chief Medical Officer
Rebecca Taub	617,500	0	4,124,382	1,521,590	604,544	0	0	6,868,016
Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer
Mardi Dier	566,042	0	3,561,539	1,313,997	554,165	0	89,346	6,085,089
Executive Vice President and Chief Financial Officer
Carole Huntsman	540,313	0	3,186,937	1,175,671	528,976	0	9,839	5,441,736
Executive Vice President and Chief Commercial Officer
Shannon Kelley	535,167	0	2,999,636	1,106,611	523,938	0	14,000	5,179,352
Executive Vice President and Chief Legal Counsel

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
Bill Sibold	$19,206,341	$12,214,250	$32,268,400	↑ +6,992,091
David Soergel	9,190,678	—	—	—
Rebecca Taub	6,868,016	5,967,206	6,928,008	↑ +900,810
Mardi Dier	6,085,089	8,751,912	—	↓ −2,666,823
Carole Huntsman	5,441,736	3,949,441	3,142,354	↑ +1,492,295
Shannon Kelley	5,179,352	4,673,764	—	↑ +505,588

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The primary objectives of the compensation program are to attract and retain highly qualified executives by providing a competitive package with significant long-term retentive value, reward executives for achieving annual operational goals and long-term strategic objectives, and align executive interests with those of stockholders.

CEO STI target (% of salary)	80%
CEO LTI target (% of salary)	—
Independent consultant	Compensia, Inc.
Clawback policy	true
Anti-hedging	true
Anti-pledging	true

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
David Soergel	PSU	2025-05-15	3,772	7,545	—	15,090	$3,710,027
Shannon Kelley	PSU	2025-03-05	1,593	3,187	—	6,374	1,892,855
Bill Sibold	PSU	2025-03-05	6,533	13,066	—	26,132	7,760,289
Bill Sibold	RSU	2025-03-05	—	—	13,066	—	4,537,560
Mardi Dier	PSU	2025-03-05	1,892	3,784	—	7,568	2,247,431
Mardi Dier	RSU	2025-03-05	—	—	3,784	—	1,314,108
Shannon Kelley	RSU	2025-03-05	—	—	3,187	—	1,106,781
Rebecca Taub	PSU	2025-03-05	2,191	4,382	—	8,764	2,602,601
Carole Huntsman	PSU	2025-03-05	1,693	3,386	—	6,772	2,011,047
Rebecca Taub	RSU	2025-03-05	—	—	4,382	—	1,521,781
David Soergel	RSU	2025-05-15	—	—	7,545	—	2,201,782
Carole Huntsman	RSU	2025-03-05	—	—	3,386	—	1,175,890
Carole Huntsman	OPTION	2025-03-05	—	—	5,703	—	1,175,671
David Soergel	OPTION	2025-05-15	—	—	12,839	—	2,201,587
Bill Sibold	OPTION	2025-03-05	—	—	22,009	—	4,537,146
Mardi Dier	OPTION	2025-03-05	—	—	6,374	—	1,313,997
Shannon Kelley	OPTION	2025-03-05	—	—	5,368	—	1,106,611
Rebecca Taub	OPTION	2025-03-05	—	—	7,381	—	1,521,590

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
David Soergel	$2,201,782	$3,710,027	$2,201,587	45.7%
Shannon Kelley	1,106,781	1,892,855	1,106,611	46.1%
Bill Sibold	4,537,560	7,760,289	4,537,146	46.1%
Mardi Dier	1,314,108	2,247,431	1,313,997	46.1%
Rebecca Taub	1,521,781	2,602,601	1,521,590	46.1%
Carole Huntsman	1,175,890	2,011,047	1,175,671	46.1%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Shannon Kelley	RSU	2,075	—	$1,208,356
Shannon Kelley	Option	2,345	243.92	—
Carole Huntsman	RSU	2,729	—	1,589,206
Carole Huntsman	Option	3,084	229	—
Shannon Kelley	RSU	3,187	—	1,855,918
Carole Huntsman	RSU	3,386	—	1,971,803
Mardi Dier	RSU	3,784	—	2,203,575
Rebecca Taub	Option	3,844	87.09	—
Shannon Kelley	RSU	3,911	—	2,277,532
Carole Huntsman	RSU	3,917	—	2,281,026
Rebecca Taub	RSU	4,339	—	2,526,773
Rebecca Taub	RSU	4,382	—	2,551,814
Rebecca Taub	Option	4,904	229	—
Carole Huntsman	Option	5,038	190.05	—
Shannon Kelley	Option	5,368	347.28	—
Shannon Kelley	Option	5,376	244.5	—
Carole Huntsman	Option	5,703	347.28	—
Shannon Kelley	PSU	6,374	—	3,711,835
Mardi Dier	Option	6,374	347.28	—
Mardi Dier	RSU	6,656	—	3,876,055
Carole Huntsman	PSU	6,772	—	3,943,606
Carole Huntsman	PSU	7,278	—	4,238,271
Rebecca Taub	Option	7,381	347.28	—
Mardi Dier	Option	7,511	251.63	—
David Soergel	RSU	7,545	—	4,393,755
Mardi Dier	PSU	7,568	—	4,407,149
Rebecca Taub	PSU	8,764	—	5,103,628
Bill Sibold	RSU	9,187	—	5,349,958
Rebecca Taub	RSU	10,000	—	5,823,400
Bill Sibold	Option	10,383	229	—
Rebecca Taub	PSU	11,572	—	6,738,838
David Soergel	Option	12,839	291.82	—
Bill Sibold	RSU	13,066	—	7,608,854
David Soergel	PSU	15,090	—	8,787,511
Mardi Dier	PSU	17,750	—	10,336,535
Bill Sibold	Option	22,009	347.28	—
Bill Sibold	PSU	24,500	—	14,267,330
Bill Sibold	RSU	25,000	—	14,558,500
Bill Sibold	PSU	26,132	—	15,217,709
Bill Sibold	PSU	50,000	—	29,117,000

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Jacqualyn A. Fouse, Ph.DIndependent · Audit · Compensation · Nominating and Governance · Newly elected	$56,792	$704,952	$0	$0	$0	$761,744
Daniel J. BrennanIndependent · Audit (Chair) · Partial-year service · Newly elected	28,646	584,451	0	0	0	613,097
Julian C. BakerIndependent · Board Chair · Nominating and Governance (Chair)	94,000	409,397	0	0	0	503,397
Richard S. Levy, M.DIndependent · Science and Technology · Nominating and Governance	85,500	409,397	0	0	0	494,897
Raymond Cheong, M.D., Ph.DIndependent · Compensation · Science and Technology (Chair) · Nominating and Governance	85,500	409,397	0	0	0	494,897
Kenneth M. BateIndependent · Compensation · Departed during FY	79,000	409,397	0	0	0	488,397
James M. DalyIndependent · Audit · Nominating and Governance	67,625	409,397	0	0	0	477,022
Paul A. Friedman, M.DNot independent · Science and Technology	59,750	409,397	0	0	0	469,147
Fred B. Craves, Ph.DIndependent · Compensation · Departed during FY	39,375	0	0	0	0	39,375

Board fee structure and ownership guideline

Annual cash retainer	$50,000
Annual equity retainer	$400,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	25,000 / 20,000 / 12,000
Stock ownership guideline	—

Total cost of the board

Component	FY2025
Cash retainers and fees	$596,188
Equity awards (grant-date value)	$3,745,785
All other compensation	$0
Total cost of the board	$4,341,973

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Madrigal Pharmaceuticals as a peer

Companies that benchmark against MDGL

21 companies name MDGL as a compensation peer

The list of companies that name MDGL as a peer is temporarily unavailable — recheck shortly.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

IONS Ionis PharmaceuticalsCYTK CytokineticsEXEL ExelixisITCI Intra-Cellular TherapiesALNY Alnylam PharmaceuticalsAPLS Apellis PharmaceuticalsNBIX Neurocrine BiosciencesHALO Halozyme TherapeuticsROIV Roivant SciencesINSM InsmedSRPT Sarepta TherapeuticsCRSP CRISPR Therapeutics AG

Peer reciprocity

The companies Madrigal Pharmaceuticals, Inc names as compensation peers that name it back in their own disclosed peer groups.

Cytokinetics (CYTK)¹²¹Apellis Pharmaceuticals (APLS)¹²²

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Exelixis	2025	Michael Morrissey	$1,306,040	$30,539,552	$0	$1,382,591	$33,239,183
2	Roivant Sciences	2025	Eric Venker	75,000	2,261,908	0	0	24,400,210
3	Halozyme Therapeutics	2025	Helen Torley	1,000,000	19,350,145	1,650,014	1,147,500	23,166,223
4	Madrigal Pharmaceuticals, Inc	2025	Bill Sibold	918,531	12,297,850	4,537,146	1,438,814	19,206,341
5	Alnylam Pharmaceuticals	2025	Yvonne Greenstreet	1,404,200	5,512,500	4,363,380	3,562,500	14,867,600
6	Insmed	2025	William Lewis	854,550	2,999,940	9,000,033	1,495,463	14,467,393
7	Neurocrine Biosciences	2025	Kyle Gano	920,000	5,750,023	5,750,006	0	13,448,935
8	Ionis Pharmaceuticals	2025	Brett Monia	1,051,776	8,444,838	1,438,105	0	13,350,777
9	Cytokinetics	2025	Robert Blum	853,069	5,150,019	5,095,918	772,715	11,881,456
10	Apellis Pharmaceuticals	2024	Cedric Francois	793,193	4,779,832	4,787,768	0	10,957,451
11	Intra-Cellular Therapies	2023	Sharon Mates	891,653	7,749,984	0	0	10,086,413
12	Sarepta Therapeutics	2025	Douglas Ingram	1,171,425	6,000,005	0	649,000	7,840,666
13	Crispr Therapeutics AG	2025	Samarth Kulkarni	768,622	3,474,900	2,768,862	659,093	7,678,477

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Madrigal Pharmaceuticals, Inc	not disclosed	PSU 33.33 · RSU 33.33 · Option 33.33	Yes — Relative TSR vs Nasdaq Biotechnology Index	Compensia, Inc.
Alnylam Pharmaceuticals	200%	PSU 50 · RSU 25 · Option 25	No	Pay Governance
Apellis Pharmaceuticals	90.74%	RSU 50 · PSU 50	not disclosed	Pay Governance
Crispr Therapeutics AG	not disclosed	not disclosed	not disclosed	Alpine Rewards, LLC
Cytokinetics	120%	RSU 50 · Options 50	not disclosed	Aon Human Capital Solutions
Exelixis	105%	PSU 50 · RSU 50	Yes — 2025 Relative TSR Goal	Aon
Halozyme Therapeutics	127.5%	PSU 50 · RSU 35 · Option 15	No	F.W. Cook & Co., Inc.
Insmed	175%	Options 75 · RSU 25	No	Willis Towers Watson (WTW)
Intra-Cellular Therapies	not disclosed	RSU 75 · PRSU 25	Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index	Aon Consulting, Inc.
Ionis Pharmaceuticals	not disclosed	PRSU 40 · Option 30 · RSU 30	Yes — Relative TSR	Aon
Neurocrine Biosciences	105%	Option 50 · PRSU 30 · RSU 20	No	Frederic W. Cook & Co., Inc.
Roivant Sciences	not disclosed	not disclosed	not disclosed	Aon
Sarepta Therapeutics	100%	PSU 50 · Option 25 · RSU 25	No	FW Cook

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-06-17	19,000,895	561,058	29,031	97.13%	Passed
2025	2025-06-20	18,720,175	208,911	21,817	98.9%	Passed
2024	2024-06-25	15,585,020	781,212	11,522	95.23%	Passed
2023	2023-06-15	13,908,736	940,302	16,130	93.67%	Passed
2022	2022-06-15	11,637,547	111,932	16,755	99.05%	Passed
2021	2021-06-17	13,492,590	230,987	8,482	98.32%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-06-17	97.13%^a
2025	2025-06-20	98.9%^b
2024	2024-06-25	95.23%^c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the results of this vote.”.

b. Approved under the standard stated in the filing — “Abstentions are not considered votes cast on Proposal 2 and will have no effect on the results of this vote.”.

c. Approved under the standard stated in the filing — “Abstentions are not considered votes cast on Proposal 2 and will have no effect on the results of this vote.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	47 : 1
CEO total compensation	$19,206,341
Median employee compensation	$403,403

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
David Soergel	Chief Medical Officer	2026-05-18	D	844	$516	$435,420	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	80	520	41,598	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	343	515	176,532	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	40	513	20,519	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	151	510	77,064	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	782	519	405,669	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	1,497	518	774,835	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	723	517	373,694	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	657	516	338,961	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	439	513	224,988	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	610	511	311,952	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	320	508	162,637	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	40	507	20,267	Common	Form 4 ↗
David Soergel	Chief Medical Officer	2026-06-01	D	1,042	496	516,561	Common	Form 4 ↗
Dividend-equivalent accruals		2026-06-17	—	6,809	—	—	6 insiders, 7 accrual rows
BAKER BROS. ADVISORS LP	Director	2026-06-17	A	908	0	0	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-06-17	A	908	0	0	Common	Form 4 ↗
Rebecca Taub	Director	2026-06-17	A	454	0	0	Common	Form 4 ↗
James M. Daly	Director	2026-06-17	A	454	0	0	Common	Form 4 ↗
Daniel J. Brennan	Director	2026-06-17	A	404	0	0	Common	Form 4 ↗
Jacqualyn A. Fouse	Director	2026-06-17	A	454	0	0	Common	Form 4 ↗
Richard S. Levy	Director	2026-06-17	A	454	0	0	Common	Form 4 ↗
Bill Sibold	Director	2026-07-17	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
Bill Sibold	Director	2026-07-17	A	50,000	—	—	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	1	551	551	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	275	546	150,070	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	110	544	59,817	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	140	543	75,984	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	269	547	147,164	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	280	555	155,414	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	153	550	84,152	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	47	549	25,797	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	680	548	372,435	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	545	545	296,869	Common	Form 4 ↗
Dividend-equivalent accruals		2026-08-15	—	1,078	—	—	1 insider, 1 accrual row
John C. Reed	Director	2026-08-15	A	647	0	0	Common	Form 4 ↗
Shannon Kelley	General Counsel	2026-08-17	D	664	515	341,940	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	362	542	196,079	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	505	540	272,796	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	644	535	344,715	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	396	534	211,542	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	520	538	279,914	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	131	528	69,152	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	160	543	86,808	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	215	539	115,891	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	640	537	343,791	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	1,040	536	557,557	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	512	533	272,944	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	368	532	195,772	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	522	530	276,781	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	347	529	183,656	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	120	546	65,565	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	761	545	414,616	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	160	538	86,019	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	218	536	116,836	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	106	534	56,611	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	60	533	31,985	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	1,539	544	837,253	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	1,202	543	652,209	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	368	542	199,324	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	687	541	371,382	Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 67 transactions

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
David Soergel	Chief Medical Officer	2026-05-18	D	844	$516	$435,420	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	80	520	41,598	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	343	515	176,532	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	40	513	20,519	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	151	510	77,064	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	782	519	405,669	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	1,497	518	774,835	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	723	517	373,694	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	657	516	338,961	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	439	513	224,988	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	610	511	311,952	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	320	508	162,637	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-22	D	40	507	20,267	Common	Form 4 ↗
David Soergel	Chief Medical Officer	2026-06-01	D	1,042	496	516,561	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-06-17	A	1,532	0	0	Derivative, Class A Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-06-17	A	908	0	0	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-06-17	A	908	0	0	Common	Form 4 ↗
James M. Daly	Director	2026-06-17	A	766	0	0	Derivative, Class A Common	Form 4 ↗
Rebecca Taub	Director	2026-06-17	A	454	0	0	Common	Form 4 ↗
Richard S. Levy	Director	2026-06-17	A	766	0	0	Derivative, Class A Common	Form 4 ↗
James M. Daly	Director	2026-06-17	A	454	0	0	Common	Form 4 ↗
Jacqualyn A. Fouse	Director	2026-06-17	A	766	0	0	Derivative, Class A Common	Form 4 ↗
Rebecca Taub	Director	2026-06-17	A	766	0	0	Derivative, Class A Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-06-17	A	1,532	0	0	Derivative, Class A Common	Form 4 ↗
Daniel J. Brennan	Director	2026-06-17	A	681	0	0	Derivative, Class A Common	Form 4 ↗
Daniel J. Brennan	Director	2026-06-17	A	404	0	0	Common	Form 4 ↗
Jacqualyn A. Fouse	Director	2026-06-17	A	454	0	0	Common	Form 4 ↗
Richard S. Levy	Director	2026-06-17	A	454	0	0	Common	Form 4 ↗
Bill Sibold	Director	2026-07-17	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
Bill Sibold	Director	2026-07-17	A	50,000	—	—	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	1	551	551	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	275	546	150,070	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	110	544	59,817	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	140	543	75,984	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	269	547	147,164	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	280	555	155,414	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	153	550	84,152	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	47	549	25,797	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	680	548	372,435	Common	Form 4 ↗
Bill Sibold	Director	2026-07-20	D	545	545	296,869	Common	Form 4 ↗
John C. Reed	Director	2026-08-15	A	1,078	0	0	Derivative, Class A Common	Form 4 ↗
John C. Reed	Director	2026-08-15	A	647	0	0	Common	Form 4 ↗
Shannon Kelley	General Counsel	2026-08-17	D	664	515	341,940	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	362	542	196,079	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	505	540	272,796	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	644	535	344,715	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	396	534	211,542	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	520	538	279,914	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	131	528	69,152	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	160	543	86,808	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	215	539	115,891	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	640	537	343,791	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	1,040	536	557,557	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	512	533	272,944	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	368	532	195,772	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	522	530	276,781	Common	Form 4 ↗
Bill Sibold	Director	2026-09-09	D	347	529	183,656	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	120	546	65,565	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	761	545	414,616	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	160	538	86,019	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	218	536	116,836	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	106	534	56,611	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	60	533	31,985	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	1,539	544	837,253	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	1,202	543	652,209	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	368	542	199,324	Common	Form 4 ↗
Bill Sibold	Director	2026-09-11	D	687	541	371,382	Common	Form 4 ↗

Sources (122 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Bill Sibold. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 47. As printed: 19,206,341. View filing ↗
Section 01, David Soergel. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 47. As printed: 9,190,678. View filing ↗
Section 01, Rebecca Taub. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 47. As printed: 6,868,016. View filing ↗
Section 01, Mardi Dier. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 47. As printed: 6,085,089. View filing ↗
Section 01, Carole Huntsman. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 47. As printed: 5,441,736. View filing ↗
Section 01, Shannon Kelley. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 47. As printed: 5,179,352. View filing ↗
Section 03, David Soergel PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Shannon Kelley PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Bill Sibold PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Bill Sibold RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Mardi Dier PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Mardi Dier RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Shannon Kelley RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Rebecca Taub PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Carole Huntsman PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Rebecca Taub RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, David Soergel RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Carole Huntsman RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Carole Huntsman OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, David Soergel OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Bill Sibold OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Mardi Dier OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Shannon Kelley OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Rebecca Taub OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: 47 : 1. View filing ↗
Section 08, Jacqualyn A. Fouse, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 761,744. View filing ↗
Section 08, Daniel J. Brennan. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 613,097. View filing ↗
Section 08, Julian C. Baker. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 503,397. View filing ↗
Section 08, Richard S. Levy, M.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 494,897. View filing ↗
Section 08, Raymond Cheong, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 494,897. View filing ↗
Section 08, Kenneth M. Bate. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 488,397. View filing ↗
Section 08, James M. Daly. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 477,022. View filing ↗
Section 08, Paul A. Friedman, M.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 469,147. View filing ↗
Section 08, Fred B. Craves, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 39,375. View filing ↗
Section 02, David Soergel 2026-05-18. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-22. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Soergel 2026-06-01. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James M. Daly 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Rebecca Taub 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James M. Daly 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jacqualyn A. Fouse 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Rebecca Taub 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Daniel J. Brennan 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Daniel J. Brennan 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jacqualyn A. Fouse 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-17. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-17. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-20. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-20. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-20. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-20. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-20. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-20. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-20. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-20. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-20. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-07-20. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John C. Reed 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John C. Reed 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Shannon Kelley 2026-08-17. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bill Sibold 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-06-17. Item 5.07 · say-on-pay result. As reported: 97.13% (votes for as printed: 19,000,895). View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-06-20. Item 5.07 · say-on-pay result. As reported: 98.9% (votes for as printed: 18,720,175). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-06-27. Item 5.07 · say-on-pay result. As reported: 95.23% (votes for as printed: 15,585,020). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 596,188 + equity 3,745,785 + all other 0 = 4,341,973, summed across the director compensation table rows.
Exelixis, Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis's own proxy. As printed: 33,239,183. View filing ↗
Roivant Sciences, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Roivant Sciences's own proxy. As printed: 24,400,210. View filing ↗
Halozyme Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics's own proxy. As printed: 23,166,223. View filing ↗
Madrigal Pharmaceuticals, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals, Inc's own proxy. As printed: 19,206,341. View filing ↗
Alnylam Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals's own proxy. As printed: 14,867,600. View filing ↗
Insmed, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Insmed's own proxy. As printed: 14,467,393. View filing ↗
Neurocrine Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. View filing ↗
Ionis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. View filing ↗
Cytokinetics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Cytokinetics's own proxy. As printed: 11,881,456. View filing ↗
Apellis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. View filing ↗
Intra-Cellular Therapies, Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular Therapies's own proxy. As printed: 10,086,413. View filing ↗
Sarepta Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sarepta Therapeutics's own proxy. As printed: 7,840,666. View filing ↗
Crispr Therapeutics AG, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Crispr Therapeutics AG's own proxy. As printed: 7,678,477. View filing ↗
Section 10a, Cytokinetics reciprocity. DEF 14A. Cytokinetics names Madrigal Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Apellis Pharmaceuticals reciprocity. DEF 14A. Apellis Pharmaceuticals names Madrigal Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗